Evotec/$EVO
1D1W1MYTD1Y5YMAX
Capital at risk
About Evotec
Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA.
- Ticker
- $EVO
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 4,461
- Headquarters
- Hamburg, Germany
- Website
- www.evotec.com
Evotec Metrics
BasicAdvanced
$570M
-
-$1.27
1.26
-
Price and volume
Market cap
$570M
Beta
1.26
52-week high
$4.27
52-week low
$1.50
Average daily volume
112K
Financial strength
Current ratio
2.333
Quick ratio
2.023
Long term debt to equity
0.622
Total debt to equity
0.715
Profitability
EBITDA (TTM)
-83.996
Gross margin (TTM)
8.46%
Net profit margin (TTM)
-27.47%
Operating margin (TTM)
-20.33%
Effective tax rate (TTM)
-7.21%
Revenue per employee (TTM)
$183,640
Management effectiveness
Return on assets (TTM)
-5.39%
Return on equity (TTM)
-26.08%
Valuation
Price to revenue (TTM)
0.332
Price to book
0.75
Price to tangible book (TTM)
1.38
Price to free cash flow (TTM)
-1.371
Free cash flow yield (TTM)
-72.91%
Free cash flow per share (TTM)
-1.123
Growth
Revenue change (TTM)
-7.72%
Earnings per share change (TTM)
26.46%
3-year revenue growth (CAGR)
-3.51%
10-year revenue growth (CAGR)
17.08%
3-year earnings per share growth (CAGR)
23.85%
10-year earnings per share growth (CAGR)
39.61%
What the Analysts think about Evotec
Analyst ratings (Buy, Hold, Sell) for Evotec stock.
Analyst projections of the future price of Evotec stock.
Bulls say / Bears say
Underlying commercial activity is improving: D&PD net sales excluding strategic partnerships rose 28% year on year, with stronger customer engagement. Just–Evotec Biologics also reported high capacity utilisation and a broader customer base. (Evotec)
A Bristol Myers Squibb programme created through Evotec’s discovery platform entered a Phase 1 study, triggering a $10m milestone. Clinical progression provides evidence that Evotec’s molecular-glue and multi-omics capabilities can generate valuable partnered assets. (Evotec)
Evotec continued to add discovery collaborations with Odyssey Therapeutics and Plectonic Biotech in autoimmune disease and oncology. These deals expand its AI, screening and biologics platforms and create potential milestone streams, although the programmes remain early stage. (PR Newswire, Evotec)
Evotec cut 2026 revenue guidance to €570m–€610m from €700m–€780m and now expects adjusted EBITDA of negative €70m–€105m. The downgrade reflects delayed milestones, slower partnership signings and weaker sales-to-revenue conversion. (Evotec)
First-half revenue fell 19.2% to €300.1m, while adjusted EBITDA deteriorated to a €42.7m loss from a €1.9m loss. Operating performance was also hit by under-utilisation, a negative gross margin and weaker revenue conversion. (MarketScreener)
Berenberg downgraded Evotec to Hold and cut its target to €3.60, citing unusually poor visibility and dependence on strategic partnerships that are not yet finalised. That makes earnings timing and the recovery case harder to assess. (MarketScreener)
Data summarised monthly by Lightyear AI. Last updated on 17 Sept 2026.
Evotec Financial Performance
Revenues and expenses
Evotec Earnings Performance
Company profitability
Upcoming events
No upcoming events
Evotec News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.